In order to consider HLA‐G as a potential target for cancer therapy, we ought to precisely determine how prevalent the expression of HLA‐G is in tumor cells derived from patients with ccRCC. The gene discussed is HLA-G; the disease is nonpapillary renal cell carcinoma.